Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Congenital Hyperinsulinism Clear all

Conditions: Hyperinsulinemic Hypoglycemia
Interventions: high carbohydrate test meal, high carbohydrate test meal after pre-treatment with rapid acting aspart insulin, high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hyperinsulinism, Diabetes, Pancreatic Diseases, Pancreatectomy; Hyperglycemia
Interventions: Bihormonal Bionic Pancreas; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 6 Years to 30 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Seizures, Hypoglycemia, Hyperammonemia
Interventions: Not listed
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: Up to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Congenital Hyperinsulinism
Interventions: Exendin (9-39), Vehicle; Drug
Lead sponsor: Diva De Leon; Other
Eligibility: Up to 12 Months
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Post-Bariatric Hypoglycemia
Interventions: Use of Continuous Glucose Monitor (CGM), Use of "Cardea Solo" monitoring; Behavioral · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Turner Syndrome, Idiopathic Short Stature
Interventions: somatropin (rDNA); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 7 Years to 14 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Congenital Hyperinsulinism, Insulinoma
Interventions: Fluorodopa F 18; Drug
Lead sponsor: Cook Children's Health Care System; Other
Eligibility: Up to 18 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2028
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Polycystic Ovary Syndrome, Anovulation, Hyperandrogenism, Insulin Resistance, Glucose Intolerance, Metabolic Complication
Interventions: Placebo, Inositol; Other · Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Hershey, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Congenital Hyperinsulinism, Hyperinsulinism, Persistent Hyperinsulinemic Hypoglycemia of Infancy, CHI, PHHI
Interventions: F-DOPA, PET scan; Drug · Radiation
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 18 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lafora Disease
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bardet-Biedl Syndrome
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: Not listed
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Congenital Hyperinsulinism
Interventions: Dasiglucagon, Standard of Care; Drug · Other
Lead sponsor: Zealand Pharma; Industry
Eligibility: 3 Months to 12 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Aurora, Colorado • Philadelphia, Pennsylvania • Fort Worth, Texas

Conditions: Hyperglycemia, Hyperlipidemia
Interventions: Olanzapine, Ziprasidone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hyperinsulinemic Hypoglycemia
Interventions: Exenatide, Acarbose, Exenatide Placebo, Acarbose Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Generalized Lipodystrophy
Interventions: mibavademab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Bethesda, Maryland • Ann Arbor, Michigan

Conditions: Hyperinsulinemic Hypoglycemia, Persistent, Congenital Hyperinsulinism, Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
Interventions: 18 F-DOPA; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 64 Years
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Congenital Hyperinsulinism
Interventions: dasiglucagon; Drug
Lead sponsor: Zealand Pharma; Industry
Eligibility: 5 Weeks to 13 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 3
States / cities: Aurora, Colorado • Philadelphia, Pennsylvania • Fort Worth, Texas

Conditions: Heart Defects, Congenital, Hyperglycemia
Interventions: Insulin, Usual Care; Drug · Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 36 Months
Enrollment: 989 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts • Ann Arbor, Michigan

Conditions: Cystic Fibrosis-related Diabetes
Interventions: Bionic Pancreas, Usual Care; Device · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 10 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hyperinsulinemic Hypoglycemia
Interventions: Glucagon RTU, Placebo; Drug · Other
Lead sponsor: Xeris Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 5
States / cities: Aurora, Colorado • Baltimore, Maryland • Boston, Massachusetts + 2 more

Conditions: Cystic Fibrosis-related Diabetes
Interventions: Oral glucose tolerance test, Continuous glucose monitoring, Dexa scan; Diagnostic Test
Lead sponsor: Katie Larson Ode; Other
Eligibility: 6 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Aurora, Colorado • Iowa City, Iowa • Minneapolis, Minnesota + 1 more

Conditions: Congenital Hyperinsulinism
Interventions: HM15136; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 2 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hyperinsulinism-Hyperammonemia Syndrome
Interventions: Vitamin E; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Congenital Hyperinsulinism (CHI), Beckwith-Wiedemann Syndrome, Insulinoma
Interventions: 18F-DOPA; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Post-Gastric Bypass Hypoglycemia

Bionic Pancreas in Children With Hyperinsulinism and Post-Pancreatectomy Diabetes

Blood Sugars in Children With Idiopathic Seizures.

Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia

Role of Nutrient Transit in Hyperinsulinemic Hypoglycemia

Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature

Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma

Inositol Supplementation to Treat PCOS (INSUPP-PCOS)

Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism

Ketogenic Diet in Lafora Disease

Genetics and Clinical Characteristics of Bardet-Biedl Syndrome

A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia

A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia

Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

SPECS: Safe Pediatric Euglycemia in Cardiac Surgery

Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes

Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery

EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis

HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)

Vitamin E Efficacy in HI/HA

18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia